Search results

CareDx (CDNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the

OUTFRONT Media OUT shares have gained 61.9% in the past six months compared with the industry’s growth of 3.3%.

This New York-based real estate investment trust (REIT) enjoys a diversified portfolio

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to

Alphabet GOOGL shares have returned 7.4% year to date (YTD), outperforming the Zacks Computer & Technology sector’s 4.1%. The company’s prospects are expected to benefit from its growing AI-powered

The Zacks Utility - Electric Power industry presents a compelling case for stable, long-term income due to its regulated nature. This framework allows utilities to recover costs and earn steady

Shares of Jones Lang LaSalle Incorporated JLL, popularly known as JLL, have gained 12.6% in the past month, outperforming the industry’s growth of 11.8%.

The company, sporting a Zacks Rank #1

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Integra LifeSciences (IART), which

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Huron

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Henry Schein (HSIC), which belongs to

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Huntington

Eli Lilly and Company LLY announced that a phase III study, ACHIEVE-4, evaluating its newly approved oral GLP-1 weight-loss pill Foundayo (orforglipron), for treating patients with type II diabetes

Intuitive Surgical’s ISRG expanding “line-of-sight” procedure opportunity underscores a compelling long-term growth runway. Management highlighted that identifiable procedures suitable for its

It has been a bumper year for Denali Therapeutics, Inc. DNLI. Shares of the company have surged 25.4% year to date compared with the industry’s gain of 2.7%. The stock has outperformed the sector

Cytokinetics, Incorporated CYTK has entered a pivotal phase following the FDA approval of its first commercial product, Myqorzo (aficamten), for the treatment of symptomatic obstructive hypertrophic

Terreno Realty Corporation TRNO strengthened its leasing momentum in April 2026 with notable activity in Washington, D.C. The company announced an early lease renewal for 68,000 square feet with a

Shares of AstroNova, Inc. (ALOT) have gained 11.3% since the company reported its earnings for the quarter ended Jan. 31, 2026, outperforming the S&P 500 index’s 3.3% increase over the same period

Shares of Prologis PLD moved higher yesterday after the industrial REIT posted better-than-expected first-quarter 2026 results and lifted its full-year outlook. The market appeared to respond